{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:02:00Z","timestamp":1790420520650,"version":"4.1.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.ijantimicag.2012.06.004","type":"journal-article","created":{"date-parts":[[2012,7,21]],"date-time":"2012-07-21T22:00:46Z","timestamp":1342908046000},"page":"297-305","source":"Crossref","is-referenced-by-count":113,"title":["Antibiotic therapy for inducible AmpC \u03b2-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?"],"prefix":"10.1016","volume":"40","author":[{"given":"P.N.A.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/0003-4819-115-8-585","article-title":"Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy","volume":"115","author":"Chow","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The structure of \u03b2-lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0015","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.39.6.1211","article-title":"A functional classification scheme for \u03b2-lactamases and its correlation with molecular structure","volume":"39","author":"Bush","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/CMR.10.2.220","article-title":"Enterobacter spp.: pathogens poised to flourish at the turn of the century","volume":"10","author":"Sanders","year":"1997","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0025","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/clind\/15.5.824","article-title":"\u03b2-Lactam resistance in Gram-negative bacteria: global trends and clinical impact","volume":"15","author":"Sanders","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.8.4.557","article-title":"\u03b2-Lactamases in laboratory and clinical resistance","volume":"8","author":"Livermore","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1128\/AAC.46.1.216-219.2002","article-title":"Postneurosurgical meningitis due to Proteus penneri with selection of a ceftriaxone-resistant isolate: analysis of chromosomal class A \u03b2-lactamase HugA and its LysR-type regulatory protein HugR","volume":"46","author":"Liassine","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0040","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/jac\/dkh151","article-title":"Analysis of AmpC \u03b2-lactamase expression and sequence in biochemically atypical ceftazidime-resistant Enterobacteriaceae from paediatric patients","volume":"53","author":"Avison","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0045","first-page":"81","article-title":"Cloning and sequencing of the \u03b2-lactamase gene and surrounding DNA sequences of Citrobacter braakii, Citrobacter murliniae, Citrobacter werkmanii, Escherichia fergusonii and Enterobacter cancerogenus","volume":"215","author":"Naas","year":"2002","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0050","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC \u03b2-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1574-6968.2005.00028.x","article-title":"Characterization of the chromosomal class A \u03b2-lactamase CKO from Citrobacter koseri","volume":"254","author":"Petrella","year":"2006","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/AAC.41.1.35","article-title":"\u03b2-Lactamases and detection of \u03b2-lactam resistance in Enterobacter spp.","volume":"41","author":"Pitout","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0065","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1046\/j.1469-0691.2002.00413.x","article-title":"Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains","volume":"8","author":"Stock","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0070","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/jac\/dkg156","article-title":"Natural antimicrobial susceptibilities of strains of \u2018unusual\u2019 Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea","volume":"51","author":"Stock","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/CMR.00039-09","article-title":"The genus Aeromonas: taxonomy, pathogenicity, and infection","volume":"23","author":"Janda","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0080","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/jinf.2000.0654","article-title":"Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia","volume":"40","author":"Ko","year":"2000","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0085","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1128\/AAC.48.8.3172-3174.2004","article-title":"CMY-13, a novel inducible cephalosporinase encoded by an Escherichia coli plasmid","volume":"48","author":"Miriagou","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0090","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/JCM.00219-10","article-title":"Extended-spectrum-\u03b2-lactamase, AmpC, and carbapenemase issues","volume":"48","author":"Thomson","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0095","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1086\/511789","article-title":"Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain","volume":"28","author":"Biller","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0100","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1086\/381551","article-title":"Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use","volume":"38","author":"Gaynes","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0105","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/AAC.01581-09","article-title":"Improving quinolone use in hospitals by using a bundle of interventions in an interrupted time series analysis","volume":"54","author":"Willemsen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0110","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/605530","article-title":"Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting","volume":"49","author":"Gottesman","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0115","series-title":"Therapeutic guidelines: antibiotic, version 14","author":"Antibiotic Expert Group","year":"2010"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0120","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1128\/AAC.01535-08","article-title":"Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa","volume":"53","author":"Pakyz","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0125","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/AAC.45.9.2628-2630.2001","article-title":"Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp.","volume":"45","author":"Kaye","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0130","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1128\/AAC.01083-07","article-title":"Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC \u03b2-lactamase: implications for antibiotic use","volume":"52","author":"Choi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archinte.162.2.185","article-title":"Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species","volume":"162","author":"Cosgrove","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1592\/phco.27.2.191","article-title":"Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundii","volume":"27","author":"Deal","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0145","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1086\/423382","article-title":"Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome","volume":"39","author":"Kang","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/ajcp\/100.1.47","article-title":"Emergence of antimicrobial resistance in Gram-negative bacilli causing bacteremia during therapy","volume":"100","author":"Siebert","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0155","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/00006454-200210000-00010","article-title":"Clinical implications of inducible \u03b2-lactamase activity in Gram-negative bacteremia in children","volume":"21","author":"Boyle","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0160","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1086\/502004","article-title":"Serratia bacteremia in a large university hospital: trends in antibiotic resistance during 10 years and implications for antibiotic use","volume":"23","author":"Choi","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0165","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1469-0691.2002.00492.x","article-title":"Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation","volume":"8","author":"Goldstein","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0170","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1469-0691.2004.00831.x","article-title":"Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?","volume":"10","author":"Livermore","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0175","unstructured":"Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. Document M100-S22. Wayne, PA: CLSI; 2012."},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0180","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0185","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodriguez-Bano","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijantimicag.2010.09.009","article-title":"Risk factors and outcome of extended-spectrum \u03b2-lactamase-producing Enterobacter cloacae bloodstream infections","volume":"37","author":"Qureshi","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0195","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1128\/AAC.00055-10","article-title":"Bacteremia due to extended-spectrum-\u03b2-lactamase-producing Enterobacter cloacae: role of carbapenem therapy","volume":"54","author":"Lee","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0200","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/AAC.34.2.337","article-title":"Outer membrane permeability and \u03b2-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents","volume":"34","author":"Nikaido","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2012.06.004_bib0205","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1111\/j.1469-0691.1999.tb00721.x","article-title":"In vitro selective concentrations of cefepime and ceftazidime for AmpC \u03b2-lactamase hyperproducer Enterobacter cloacae variants","volume":"5","author":"Negri","year":"1999","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0210","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/cc8941","article-title":"Prospective monitoring of cefepime in intensive care unit adult patients","volume":"14","author":"Chapuis","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0215","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1213\/01.ANE.0000077077.54084.B0","article-title":"Cefepime versus cefpirome: the importance of creatinine clearance","volume":"97","author":"Lipman","year":"2003","journal-title":"Anesth Analg"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0220","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.43.10.2559","article-title":"Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing","volume":"43","author":"Lipman","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0225","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1592\/phco.23.3.310.32108","article-title":"Disposition of cefepime in the central nervous system of patients with external ventricular drains","volume":"23","author":"Rhoney","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0230","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.diagmicrobio.2005.09.007","article-title":"Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies","volume":"54","author":"Lodise","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0235","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1179\/joc.2003.15.2.134","article-title":"Diffusion of cefepime into cancellous and cortical bone tissue","volume":"15","author":"Breilh","year":"2003","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/pupt.2000.0269","article-title":"Pharmacokinetic population study to describe cefepime lung concentrations","volume":"14","author":"Breilh","year":"2001","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0245","first-page":"425","article-title":"Cefepime","volume":"vol. 1","author":"Endimiani","year":"2010"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0250","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/00313020125000","article-title":"Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents","volume":"33","author":"Bell","year":"2001","journal-title":"Pathology"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0255","unstructured":"Turnidge J, Gottlieb T, Mitchell D, Pearson J, Bell J. Gram-negative survey: 2008 antimicrobial susceptibility report. Australian Group on Antimicrobial Resistance (AGAR); 2011. http:\/\/www.agargroup.org\/files\/AGAR%20GNB08%20Report%20FINAL.pdf [accessed 26.06.12]."},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0260","unstructured":"Turnidge J, Gottlieb T, Mitchell D, Pearson J, Bell J. Gram-negative survey: 2009 antimicrobial susceptibility report. Australian Group on Antimicrobial Resistance (AGAR); 2011. http:\/\/www.agargroup.org\/files\/AGAR%20GNB09%20Final%20Report.pdf [accessed 26.06.12]."},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0265","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1128\/AAC.48.4.1313-1319.2004","article-title":"Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized \u03b2-lactamases","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0270","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2011.11.023","volume":"34","author":"Bertrand","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0275","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3. EUCAST; 2011. http:\/\/www.eucast.org\/clinical_breakpoints\/ [accessed 20.11.11]."},{"issue":"Suppl. B","key":"10.1016\/j.ijantimicag.2012.06.004_bib0280","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/jac\/32.suppl_B.187","article-title":"Cefepime versus cefotaxime in the treatment of lower respiratory tract infections","volume":"32","author":"Barckow","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0285","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/AAC.38.3.415","article-title":"Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome","volume":"38","author":"Kieft","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0290","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/clinids\/20.1.56","article-title":"Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with Gram-negative bacteremia","volume":"20","author":"Schrank","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0295","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/archsurg.1997.01430360040008","article-title":"A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem\u2013cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group","volume":"132","author":"Barie","year":"1997","journal-title":"Arch Surg"},{"issue":"Suppl.","key":"10.1016\/j.ijantimicag.2012.06.004_bib0300","first-page":"18","article-title":"A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis","volume":"177","author":"Berne","year":"1993","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0305","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1179\/joc.1997.9.3.213","article-title":"Cefepime versus ceftazidime in the treatment of lower respiratory tract infections","volume":"9","author":"Aufiero","year":"1997","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0310","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00006454-200103000-00033","article-title":"Empiric use of cefepime in the treatment of lower respiratory tract infections in children","volume":"20","author":"Bradley","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0315","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/jac\/42.4.511","article-title":"Cefepime versus imipenem\u2013cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study group of Infectious Diseases in Cancer)","volume":"42","author":"Biron","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0320","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00006454-200203000-00009","article-title":"Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer","volume":"21","author":"Chuang","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0325","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000007228","article-title":"A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients","volume":"45","author":"Wang","year":"1999","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0330","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/clinids\/23.3.454","article-title":"Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species","volume":"23","author":"Sanders","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0335","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1128\/AAC.01487-06","article-title":"Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms","volume":"51","author":"Bhat","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0340","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/jac\/dki448","article-title":"Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials","volume":"57","author":"Paul","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0345","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: a systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0350","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1086\/655132","article-title":"Cefepime and death: reality to the rescue","volume":"51","author":"Freifeld","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0355","unstructured":"US Food and Drug Administration. NDA 50-679 cefepime hydrochloride, statistical evaluation of mortality risk. FDA; 2008. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/UCM167309.pdf [accessed 29.09.11]."},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0360","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/jac\/dkr138","article-title":"Is cefepime safe for clinical use? A Bayesian viewpoint","volume":"66","author":"Kalil","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0365","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00467-003-1333-8","article-title":"Cefepime-induced non-convulsive status epilepticus in a peritoneal dialysis patient","volume":"19","author":"Alpay","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0370","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.7326\/0003-4819-135-11-200112040-00027","article-title":"Severe neurotoxicity of cefepime in uremic patients","volume":"135","author":"Barbey","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0375","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00134-001-1170-9","article-title":"Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure","volume":"28","author":"Chatellier","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0380","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1212\/01.wnl.0000187079.12413.6a","article-title":"Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function","volume":"65","author":"Capparelli","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0385","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1023\/A:1011229421275","article-title":"Neuropsychiatric symptoms during cefepime treatment","volume":"23","author":"Diemont","year":"2001","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0390","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0002-9343(01)00767-7","article-title":"Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure","volume":"111","author":"Martinez-Rodriguez","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0395","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/516917","article-title":"Rapid emergence of resistance to cefepime during treatment","volume":"25","author":"Limaye","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0400","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/AAC.33.4.498","article-title":"Activity of cefepime against ceftazidime- and cefotaxime-resistant Gram-negative bacteria and its relationship to \u03b2-lactamase levels","volume":"33","author":"Fung-Tomc","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0405","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/17460913.2.3.297","article-title":"Extended-spectrum cephalosporinases: structure, detection and epidemiology","volume":"2","author":"Nordmann","year":"2007","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0410","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1586\/14787210.6.6.805","article-title":"Cefepime: a reappraisal in an era of increasing antimicrobial resistance","volume":"6","author":"Endimiani","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0415","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.18.3.382","article-title":"Induction of \u03b2-lactamase by various \u03b2-lactam antibiotics in Enterobacter cloacae","volume":"18","author":"Minami","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0420","first-page":"309","article-title":"Penicillins and \u03b2-lactam inhibitors","volume":"vol. 1","author":"Chambers","year":"2010"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0425","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/25.2.199","article-title":"Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed class I \u03b2-lactamases","volume":"25","author":"Akova","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0430","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2334-10-72","article-title":"Comparative in vitro activity of meropenem, imipenem and piperacillin\/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study","volume":"10","author":"Joly-Guillou","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0435","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.diagmicrobio.2007.09.006","article-title":"Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results","volume":"60","author":"Turner","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0440","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.diagmicrobio.2009.08.020","article-title":"Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999\u20132008)","volume":"65","author":"Rhomberg","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0445","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1469-0691.2007.01943.x","article-title":"Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the Tigecycline Evaluation and Surveillance Trial","volume":"14","author":"Rodloff","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0450","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0732-8893(97)00064-3","article-title":"Inducible Amp C \u03b2-lactamase producing Gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE)","volume":"28","author":"Pfaller","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0455","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1128\/AAC.00066-11","article-title":"Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study","volume":"55","author":"Karlowsky","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. D","key":"10.1016\/j.ijantimicag.2012.06.004_bib0460","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/41.suppl_4.25","article-title":"\u03b2-Lactamase-mediated resistance and opportunities for its control","volume":"41","author":"Livermore","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0465","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/AAC.48.5.1688-1698.2004","volume":"48","author":"Stearne","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0470","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.7164\/antibiotics.48.1027","article-title":"Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (\u03b2-lactamase derepressed mutants)","volume":"48","author":"Higashitani","year":"1995","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0475","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14787210.5.3.365","article-title":"Piperacillin\u2013tazobactam: a \u03b2-lactam\/\u03b2-lactamase inhibitor combination","volume":"5","author":"Gin","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0480","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/jac\/dkn155","article-title":"Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia","volume":"62","author":"Marcos","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0485","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1128\/AAC.47.6.1882-1886.2003","article-title":"Treatment with a broad-spectrum cephalosporin versus piperacillin\u2013tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species","volume":"47","author":"Schwaber","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0490","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/jac\/dkq348","article-title":"Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data","volume":"66","author":"Zelenitsky","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0495","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1592\/phco.31.8.767","article-title":"The Retrospective Cohort of Extended-Infusion Piperacillin\u2013Tazobactam (RECEIPT) Study: a multicenter study","volume":"31","author":"Yost","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0500","series-title":"Kucers\u2019 the use of antibiotics","article-title":"Trimethoprim, co-trimoxazole and related agents","author":"Turnidge","year":"2010"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0505","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/14787210.6.5.593","article-title":"Potential of old-generation antibiotics to address current need for new antibiotics","volume":"6","author":"Falagas","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0510","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archinte.163.4.402","article-title":"Trimethoprim\u2013sulfamethoxazole revisited","volume":"163","author":"Masters","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0515","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/320532","article-title":"Resistance to trimethoprim\u2013sulfamethoxazole","volume":"32","author":"Huovinen","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0520","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1469-0691.2010.03277.x","article-title":"Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998\u20132007","volume":"17","author":"Al-Hasan","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0525","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1592\/phco.31.9.912","article-title":"Revisiting \u201colder\u201d antimicrobials in the era of multidrug resistance","volume":"31","author":"Pogue","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0530","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/jcp.21.2.202","article-title":"Trimethoprim: laboratory and clinical studies","volume":"21","author":"Darrell","year":"1968","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0535","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/clinids\/4.2.332","article-title":"Clinical evaluation of intravenous trimethoprim\u2013sulfamethoxazole for serious infections","volume":"4","author":"Schmidt","year":"1982","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0540","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/00365548709032425","article-title":"Enterobacter meningitis\u2014treatment complicated by emergence of mutants resistant to cefotaxime","volume":"19","author":"Ralph","year":"1987","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0545","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/clind\/16.6.772","article-title":"Antibiotic therapy for Enterobacter meningitis: a retrospective review of 13 episodes and review of the literature","volume":"16","author":"Wolff","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0550","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-100-6-881","article-title":"Trimethoprim\u2013sulfamethoxazole for bacterial meningitis","volume":"100","author":"Levitz","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0555","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/11.4.385","article-title":"Ventricular cerebrospinal fluid concentrations of trimethoprim\u2013sulphamethoxazole","volume":"11","author":"Wang","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0560","first-page":"1061","article-title":"Antibacterial agents","volume":"vol. 1","author":"Yao","year":"2011"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0565","first-page":"475","article-title":"Sulfonamides and trimethoprim","volume":"vol. 1","author":"Zinner","year":"2010"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0570","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/clinids\/4.2.562","article-title":"Intravenous pharmacokinetics and in vitro bactericidal activity of trimethoprim\u2013sulfamethoxazole","volume":"4","author":"Spicehandler","year":"1982","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0575","first-page":"86","article-title":"The treatment of meningitis in infants with co-trimoxazole administered parenterally","volume":"8","author":"Sabel","year":"1976","journal-title":"Scand J Infect Dis Suppl"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0580","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.surneu.2004.06.018","article-title":"Enterobacter meningitis: organism susceptibilities, antimicrobial therapy and related outcomes","volume":"63","author":"Foster","year":"2005","journal-title":"Surg Neurol"},{"issue":"Suppl. 7","key":"10.1016\/j.ijantimicag.2012.06.004_bib0585","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1007\/BF01715834","article-title":"Double-blind comparative study of ofloxacin (Hoe 280) and trimethoprim\u2013sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease","volume":"19","author":"Boye","year":"1991","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0590","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1503\/cmaj.111152","article-title":"Considerations when prescribing trimethoprim\u2013sulfamethoxazole","volume":"183","author":"Ho","year":"2012","journal-title":"CMAJ"},{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2012.06.004_bib0595","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1007\/BF01643198","article-title":"Hematological side effects of co-trimoxazole","volume":"15","author":"Heimpel","year":"1987","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0600","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/clinids\/4.2.429","article-title":"Adverse reactions to trimethoprim\u2013sulfamethoxazole","volume":"4","author":"Lawson","year":"1982","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0605","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/00000441-199602000-00006","article-title":"Case report: severe hyperkalemia in a geriatric patient receiving standard doses of trimethoprim\u2013sulfamethoxazole","volume":"311","author":"Perlmutter","year":"1996","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0610","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1590\/S1807-59322009000100014","article-title":"Severe and prolonged cholestasis caused by trimethoprim\u2013sulfamethoxazole: a case report","volume":"64","author":"Faria","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0615","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.5858\/2000-124-1800-AFHFIA","article-title":"Acute fulminant hepatic failure in a woman treated with phenytoin and trimethoprim\u2013sulfamethoxazole","volume":"124","author":"Ilario","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0620","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.ju.0000130653.74548.d6","article-title":"Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children","volume":"172","author":"Karpman","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0625","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1473-3099(06)70414-5","article-title":"Severe and protracted hypoglycaemia associated with co-trimoxazole use","volume":"6","author":"Strevel","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0630","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00000441-200606000-00011","article-title":"Trimethoprim\u2013sulfamethoxazole associated rhabdomyolysis in a patient with AIDS: case report and review of the literature","volume":"331","author":"Walker","year":"2006","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0635","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s001340050048","article-title":"Trimethoprim\u2013sulfamethoxazole-induced aseptic meningitis: case report and literature review","volume":"26","author":"Capra","year":"2000","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0640","first-page":"80","article-title":"Trimethoprim\u2013sulfamethoxazole induced aseptic meningitis in a renal transplant patient","volume":"55","author":"Muller","year":"2001","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0645","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-2006-950393","article-title":"Cotrimoxazole-induced psychosis: a case report and review of literature","volume":"39","author":"Weis","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0650","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/jac\/dkp050","article-title":"Effect of long-term trimethoprim\/sulfamethoxazole treatment on resistance and integron prevalence in the intestinal flora: a randomized, double-blind, placebo-controlled trial in children","volume":"63","author":"van der Veen","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0655","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/jac\/dkn311","article-title":"Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies","volume":"62","author":"Kelesidis","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0660","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijantimicag.2009.10.005","article-title":"Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients","volume":"35","author":"Falagas","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0665","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0670","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijantimicag.2011.01.012","article-title":"What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline","volume":"37","author":"Livermore","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0675","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","article-title":"Fosfomycin: use beyond urinary tract and gastrointestinal infections","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0680","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1086\/505494","article-title":"Tigecycline: a critical analysis","volume":"43","author":"Stein","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0685","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1469-0691.2011.03734.x","article-title":"Colistin: new lessons on an old antibiotic","volume":"18","author":"Yahav","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0690","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1473-3099(11)70177-3","article-title":"Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis","volume":"11","author":"Tasina","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.06.004_bib0695","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","article-title":"Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections","volume":"6","author":"Li","year":"2006","journal-title":"Lancet Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857912002580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857912002580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T16:03:13Z","timestamp":1642867393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857912002580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":139,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0924857912002580"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.06.004","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}